ERBB2 and breast cancer: Germline BRCA mutations have been detected in approximately 9.7% of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic BC (mBC), with prevalence being higher in patients with triple-negative BC (TNBC; 10–20%) than in those with hormone receptor (HR)-positive BC (2–8%) [4–6].